Maria Yoshida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Yoshida has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Takao Masaki
Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan
4 shared publications - Ayumu Nakashima
Department of Nephrology, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan
3 shared publications - Kensuke Sasaki
Department of Nephrology Hiroshima University Hospital Hiroshima Japan
2 shared publications Naoki Ishiuchi
Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan
2 shared publicationsGo Matsuda
Department of Stem Cell Biology and Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
1 shared publicationHiroshi Watanabe
Department of General Surgery, Sanyo Hospital, Fukuyama, Japan
1 shared publication
Latest Publications
- Open Access
- 6 January 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (1) , 12
Relapsing peritoneal dialysis‑associated peritonitis caused by Pseudomonas oryzihabitans with concurrent tunnel infection: a case report and literature review
Peritoneal dialysis (PD)-associated peritonitis is linked to an increased risk of catheter removal and PD discontinuation, with these risks occurring more frequently in relapsing peritonitis than in primary peritonitis. Relapses are often attributed to persistent infection originating from the PD catheter, including tunnel infection (TI). Although Pseudomonas oryzihabitans is a commensal bacterium and recognized opportunistic pathogen, only a limited number of cases of P. oryzihabitans peritonitis—and none involving relapsing peritonitis with concurrent TI—have been reported. A 73-year-old Japanese man undergoing PD presented with abdominal pain, fatigue, fever, and decreased PD fluid drainage. He was diagnosed with PD-associated peritonitis caused by P. oryzihabitans , which was preceded by a persistent exit-site infection due to different organisms. A 21-day course of antimicrobial therapy combined with peritoneal lavage led to clinical improvement. However, 27 days after completing treatment, he developed relapsing peritonitis due to P. oryzihabitans , complicated by TI suspected on computed tomography. However, the patient declined catheter removal and chose outpatient intraperitoneal antibiotics. The relapse resolved, but persistent yellow drainage prompted cuff-shaving surgery. We present a case of peritonitis caused by P. oryzihabitans , initially presenting with exit site infection and later complicated by TI at recurrence, that was successfully treated without PD catheter removal. This case suggests that cuff-shaving combined with appropriate antimicrobial therapy may be an effective treatment option for P. oryzihabitans peritonitis when the peritonitis and catheter infection are not caused by the same organism.
- 6 January 2026
- Published by Springer Nature in CEN Case Reports
- Vol. 15 (1) , 12
Open AccessRelapsing peritoneal dialysis‑associated peritonitis caused by Pseudomonas oryzihabitans with concurrent tunnel infection: a case report and literature review
Peritoneal dialysis (PD)-associated peritonitis is linked to an increased risk of catheter removal and PD discontinuation, with these risks occurring more frequently in relapsing peritonitis than in primary peritonitis. Relapses are often attributed to persistent infection originating from the PD catheter, including tunnel infection (TI). Although Pseudomonas oryzihabitans is a commensal bacterium and recognized opportunistic pathogen, only a limited number of cases of P. oryzihabitans peritonitis—and none involving relapsing peritonitis with concurrent TI—have been reported. A 73-year-old Japanese man undergoing PD presented with abdominal pain, fatigue, fever, and decreased PD fluid drainage. He was diagnosed with PD-associated peritonitis caused by P. oryzihabitans , which was preceded by a persistent exit-site infection due to different organisms. A 21-day course of antimicrobial therapy combined with peritoneal lavage led to clinical improvement. However, 27 days after completing treatment, he developed relapsing peritonitis due to P. oryzihabitans , complicated by TI suspected on computed tomography. However, the patient declined catheter removal and chose outpatient intraperitoneal antibiotics. The relapse resolved, but persistent yellow drainage prompted cuff-shaving surgery. We present a case of peritonitis caused by P. oryzihabitans , initially presenting with exit site infection and later complicated by TI at recurrence, that was successfully treated without PD catheter removal. This case suggests that cuff-shaving combined with appropriate antimicrobial therapy may be an effective treatment option for P. oryzihabitans peritonitis when the peritonitis and catheter infection are not caused by the same organism.
- Open Access
- 25 July 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (1) , 85-100
Overexpression of Thrombomodulin in Adipose-Derived Mesenchymal Stem Cells Reduces Thrombogenic Risk and Enhances Therapeutic Efficacy
Key Points: Thrombomodulin on the cell surface acts as an anticoagulant and antifibrinolytic factor by binding to thrombin. Enhancement of thrombomodulin expression reduced renal infarction and pulmonary embolism induced by adipose-derived mesenchymal stem cells. Adipose-derived mesenchymal stem cells with enhanced thrombomodulin potentiated anti-inflammation and antifibrotic effects. Background: Adipose-derived mesenchymal stem cells (ASCs) are expected to be a new therapy for organ injury; however, they were reported to have procoagulant activity, raising concerns about thrombogenic risk. Thrombomodulin acts as an anticoagulant factor by binding to thrombin, leading to the hypothesis that ASCs overexpressing thrombomodulin (TM-ASCs) could be safely used for cell therapy by reducing the risk of thromboembolism. Methods: TM-ASCs were generated using adeno-associated virus carrying thrombomodulin cDNA. To examine the risk of ASC-induced renal infarction, ASCs were administered through renal artery into rats with unilateral ischemia-reperfusion injury (IRI) and contralateral nephrectomy. To assess the risk of ASC-induced pulmonary embolism, ASCs were injected into rats through tail vein. In addition, we examined whether TM-ASCs potently inhibited inflammatory cell infiltration and kidney fibrosis in IRI rats. Furthermore, we explored synthetic compounds that enhanced thrombomodulin expression in ASCs. Results: Overexpression of thrombomodulin using adeno-associated virus reduced rat deaths related to renal infarction and pulmonary embolism induced by ASCs. TM-ASCs alleviated renal inflammation and fibrosis potently in IRI rats. The therapeutic mechanism of TM-ASCs involved increased prostaglandin E2 secretion, a shift in the macrophage phenotype to immunosuppressive M2 in vitro , and potent M2 macrophage polarization in the damaged areas in vivo. We produced ASCs with enhanced thrombomodulin expression by pretreatment with a selective inhibitory kappa-B kinase- β inhibitor. These ASCs also improved thrombotic mortality and markedly attenuated kidney fibrosis induced by IRI, similar to TM-ASCs generated by adeno-associated virus. ASCs with enhanced thrombomodulin expression by inhibitory kappa-B kinase- β inhibitor also increased prostaglandin E2 secretion, leading to a more pronounced polarization of M2 macrophages. Conclusions: ASCs with enhanced thrombomodulin expression eliminated the risk of thrombosis and reinforced therapeutic efficacy.
- 25 July 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (1) , 85-100
Open AccessOverexpression of Thrombomodulin in Adipose-Derived Mesenchymal Stem Cells Reduces Thrombogenic Risk and Enhances Therapeutic Efficacy
Key Points: Thrombomodulin on the cell surface acts as an anticoagulant and antifibrinolytic factor by binding to thrombin. Enhancement of thrombomodulin expression reduced renal infarction and pulmonary embolism induced by adipose-derived mesenchymal stem cells. Adipose-derived mesenchymal stem cells with enhanced thrombomodulin potentiated anti-inflammation and antifibrotic effects. Background: Adipose-derived mesenchymal stem cells (ASCs) are expected to be a new therapy for organ injury; however, they were reported to have procoagulant activity, raising concerns about thrombogenic risk. Thrombomodulin acts as an anticoagulant factor by binding to thrombin, leading to the hypothesis that ASCs overexpressing thrombomodulin (TM-ASCs) could be safely used for cell therapy by reducing the risk of thromboembolism. Methods: TM-ASCs were generated using adeno-associated virus carrying thrombomodulin cDNA. To examine the risk of ASC-induced renal infarction, ASCs were administered through renal artery into rats with unilateral ischemia-reperfusion injury (IRI) and contralateral nephrectomy. To assess the risk of ASC-induced pulmonary embolism, ASCs were injected into rats through tail vein. In addition, we examined whether TM-ASCs potently inhibited inflammatory cell infiltration and kidney fibrosis in IRI rats. Furthermore, we explored synthetic compounds that enhanced thrombomodulin expression in ASCs. Results: Overexpression of thrombomodulin using adeno-associated virus reduced rat deaths related to renal infarction and pulmonary embolism induced by ASCs. TM-ASCs alleviated renal inflammation and fibrosis potently in IRI rats. The therapeutic mechanism of TM-ASCs involved increased prostaglandin E2 secretion, a shift in the macrophage phenotype to immunosuppressive M2 in vitro , and potent M2 macrophage polarization in the damaged areas in vivo. We produced ASCs with enhanced thrombomodulin expression by pretreatment with a selective inhibitory kappa-B kinase- β inhibitor. These ASCs also improved thrombotic mortality and markedly attenuated kidney fibrosis induced by IRI, similar to TM-ASCs generated by adeno-associated virus. ASCs with enhanced thrombomodulin expression by inhibitory kappa-B kinase- β inhibitor also increased prostaglandin E2 secretion, leading to a more pronounced polarization of M2 macrophages. Conclusions: ASCs with enhanced thrombomodulin expression eliminated the risk of thrombosis and reinforced therapeutic efficacy.
- Open Access
- 29 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16920
Comparison of the Therapeutic Effects of Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells on Renal Fibrosis
Mesenchymal stem cells (MSCs) have attracted a great deal of interest as a therapeutic tool for renal fibrosis. Although both adipose-derived and bone marrow-derived MSCs (ADSCs and BMSCs, respectively) suppress renal fibrosis, which of these two has a stronger therapeutic effect remains unclear. This study aimed to compare the antifibrotic effects of ADSCs and BMSCs extracted from adipose tissue and bone marrow derived from the same rats. When cultured in serum-containing medium, ADSCs had a more potent inhibitory effect than BMSCs on renal fibrosis induced by ischemia-reperfusion injury in rats. ADSCs and BMSCs cultured in serum-free medium were equally effective in suppressing renal fibrosis. Mice infused with ADSCs (serum-containing or serum-free cultivation) had a higher death rate from pulmonary embolism than those infused with BMSCs. In vitro, mRNA levels of tissue factor, tumor necrosis factor-α-induced protein 6 and prostaglandin E synthase were higher in ADSCs than in BMSCs, while that of vascular endothelial growth factor was higher in BMSCs than in ADSCs. Although ADSCs had a stronger antifibrotic effect, these findings support the consideration of thromboembolism risk in clinical applications. Our results emphasize the importance of deciding between ADSCs and BMSCs based upon the target disease and culture method.
- 29 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16920
Open AccessComparison of the Therapeutic Effects of Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells on Renal Fibrosis
Mesenchymal stem cells (MSCs) have attracted a great deal of interest as a therapeutic tool for renal fibrosis. Although both adipose-derived and bone marrow-derived MSCs (ADSCs and BMSCs, respectively) suppress renal fibrosis, which of these two has a stronger therapeutic effect remains unclear. This study aimed to compare the antifibrotic effects of ADSCs and BMSCs extracted from adipose tissue and bone marrow derived from the same rats. When cultured in serum-containing medium, ADSCs had a more potent inhibitory effect than BMSCs on renal fibrosis induced by ischemia-reperfusion injury in rats. ADSCs and BMSCs cultured in serum-free medium were equally effective in suppressing renal fibrosis. Mice infused with ADSCs (serum-containing or serum-free cultivation) had a higher death rate from pulmonary embolism than those infused with BMSCs. In vitro, mRNA levels of tissue factor, tumor necrosis factor-α-induced protein 6 and prostaglandin E synthase were higher in ADSCs than in BMSCs, while that of vascular endothelial growth factor was higher in BMSCs than in ADSCs. Although ADSCs had a stronger antifibrotic effect, these findings support the consideration of thromboembolism risk in clinical applications. Our results emphasize the importance of deciding between ADSCs and BMSCs based upon the target disease and culture method.
- Open Access
Lower Geriatric Nutritional Risk Index (GNRI) Is Associated with Higher Risk of Fractures in Patients Undergoing Hemodialysis
Background: Although malnutrition and bone fracture are both major complications in patients undergoing hemodialysis, their association has not been clarified. The aim of our study was to clarify the association between the geriatric nutritional risk index (GNRI), an indicator of nutritional status, and the incidence of bone fractures in patients undergoing hemodialysis. Methods: We included 1342 registered patients undergoing hemodialysis and performed a post hoc analysis. We divided patients into the high GNRI group (≥92), considered to have a low risk of malnutrition, and the low GNRI group (GNRI groups was evaluated by the Kaplan–Meier method. Cox proportional hazards models were used to identify the risk factors for fractures requiring hospitalization. All results were stratified by sex. Results: New bone fractures developed in 108 (8.0%) patients in 5 years of follow-up. Bone fractures occurred more frequently in the low GNRI group compared with the high GNRI group (HR: 3.51, 95% CI: 1.91–6.42, p < 0.01 in males; HR: 2.47, 95% CI: 1.52–4.03, p < 0.01 in females). A low GNRI was significantly associated with an increased incidence of bone fractures, even after adjustment for covariates. However, the serum levels of calcium, phosphate, parathyroid hormone, and alkaline phosphatase were not associated with the incidence of bone fractures. Conclusions: A low GNRI is an independent risk factor for bone fractures in patients undergoing hemodialysis. Early intervention for the low GNRI group may be important in preventing the occurrence of fractures.
Open AccessLower Geriatric Nutritional Risk Index (GNRI) Is Associated with Higher Risk of Fractures in Patients Undergoing Hemodialysis
Background: Although malnutrition and bone fracture are both major complications in patients undergoing hemodialysis, their association has not been clarified. The aim of our study was to clarify the association between the geriatric nutritional risk index (GNRI), an indicator of nutritional status, and the incidence of bone fractures in patients undergoing hemodialysis. Methods: We included 1342 registered patients undergoing hemodialysis and performed a post hoc analysis. We divided patients into the high GNRI group (≥92), considered to have a low risk of malnutrition, and the low GNRI group (GNRI groups was evaluated by the Kaplan–Meier method. Cox proportional hazards models were used to identify the risk factors for fractures requiring hospitalization. All results were stratified by sex. Results: New bone fractures developed in 108 (8.0%) patients in 5 years of follow-up. Bone fractures occurred more frequently in the low GNRI group compared with the high GNRI group (HR: 3.51, 95% CI: 1.91–6.42, p < 0.01 in males; HR: 2.47, 95% CI: 1.52–4.03, p < 0.01 in females). A low GNRI was significantly associated with an increased incidence of bone fractures, even after adjustment for covariates. However, the serum levels of calcium, phosphate, parathyroid hormone, and alkaline phosphatase were not associated with the incidence of bone fractures. Conclusions: A low GNRI is an independent risk factor for bone fractures in patients undergoing hemodialysis. Early intervention for the low GNRI group may be important in preventing the occurrence of fractures.